said it has received full approval from the FDA for its drug Rebrevant plus chemotherapy as a first-line treatment for non-small cell lung cancer with EGFR exon 20 insertion mutations. The ...

In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat ...

Johnson & Johnson JNJ announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving ...

The drug first came to the market in 2021 as a post-chemo treatment for NSCLC patients with EGFR exon 20 mutations. The new green light comes on the back of the MARIPOSA-2 trial date – reported ...

patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy ...

with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations. These mutations are identified by an FDA-approved test in patients. Sunvozertinib, an irreversible EGFR ...